The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
This is a prospective observation study to evaluate the role of gut microbiome in DLBCL patients treated by glofitamab.
Study Type
OBSERVATIONAL
Enrollment
30
Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients.
Changes in gut microbiome
Characterization of the compositional and functional modifications of gut microbiome in DLBCL patients treated with glofitamab from baseline to 1 year after the end of treatment.
Time frame: 2 years
Correlation between gut microbiome and therapy outcomes in terms of response and toxicity
Correlation between gut microbiome and therapy outcomes in terms of response and toxicity
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.